LEO Pharma is eligible to receive up to $1.7bn in total payments, including a $250m upfront payment. The company is also eligible for tiered royalties on sales of oral STAT6 products, while Gilead ...

LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.

About LEO Pharma. LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society.

LEO Pharma is eligible to receive up to $1.7 billion in total payments, including an upfront payment of $250 million. LEO Pharma may also get tiered royalties ranging from high single-digit to mid ...

Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics ...

LEO Pharma may receive tiered royalties ranging from high single-digit to mid-teens on sales of topical STAT6 products. The transaction is expected to reduce Gilead's GAAP and non-GAAP 2025 ...

Leo Pharma is on the rebound. The 115-year-old Danish private company cut its operating costs by 14% in 2023 while increasing its revenue by 7%.

Timber Pharmaceuticals TMBR announced its definitive agreement to be acquired by LEO Pharma, a company focused on developing innovative solutions forpeople with skin conditions.Following this news ...

Leo Pharma is launching a new U.S. healthcare awareness campaign aimed at doctors to boost their understanding of a specific type of eczema. Called “Talk to the Hand,” this campaign aims to ...

LEO Pharma thrombosis business unit executive vice-president Jean Monin stated: “We are excited to partner with Junshi Biosciences, supplementing LEO Pharma’s Thrombosis business, ...

As part of the transaction, LEO Pharma has agreed to provide Timber with a bridge loan of up to $3.0 million, subject to certain conditions.